Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to participate in the Piper Jaffray Healthcare Conference on Tuesday, November 27
November 19, 2018
· 1 min read